Strategy of reducing coronary risk and the use of drugs

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacovigilance

Background:

• Current strategies for primary prevention of coronary heart disease (CHD) show inconclusive results in moderate-risk populations.
• Intervention in high-risk individuals may offer greater benefits, necessitating pharmaceutical treatments for hypertension and hypercholesterolemia.

Purpose of the Study:

• To advocate for a reconsideration of primary CHD prevention strategies.
• To highlight the need for rigorous long-term safety testing of drugs used in primary prevention.
• To call for the establishment of drug data banks for monitoring disease incidence related to drug use.

Main Methods:

• Review of recent clinical trial results for CHD risk reduction.
• Analysis of the necessity for drug intervention in high-risk patients.
• Examination of historical drug safety issues identified through clinical trials.

Main Results:

• Trials for moderate-risk CHD prevention have yielded disappointing and inconclusive outcomes.
• Effective risk reduction in high-risk individuals often requires pharmacotherapy for hypertension and hypercholesterolemia.
• Many widely used preventive drugs lack rigorous long-term safety data, as evidenced by past issues with clofibrate and thiazides.

Conclusions:

• A selective approach focusing on high-risk individuals is advocated for primary CHD prevention.
• There is an urgent need for more clinical trials to ensure drug safety and prevent adverse events.
• Establishing drug data banks is crucial for monitoring the long-term safety and efficacy of preventive cardiovascular medications.